Functional models of Parkinson's disease: A valuable tool in the development of novel therapies
Identifieur interne : 000D96 ( Main/Exploration ); précédent : 000D95; suivant : 000D97Functional models of Parkinson's disease: A valuable tool in the development of novel therapies
Auteurs : Peter Jenner [Royaume-Uni]Source :
- Annals of Neurology [ 0364-5134 ] ; 2008-12.
Abstract
Functional models of Parkinson's disease (PD) have led to effective treatment for the motor symptoms. Toxin‐based models, such as the 6‐hydroxydopamine–lesioned rat and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine–treated primate, have resulted in novel dopaminergic therapies and new therapeutic strategies. They have also been used to study processes underlying motor complications, particularly dyskinesia, and for developing pharmacological approaches to dyskinesia avoidance and suppression. Symptomatic models of PD based on nigrostriatal degeneration have a high degree of predictability of clinical effect of dopaminergic drugs on motor symptoms in humans. However, the effects of nondopaminergic drugs in these models do not translate effectively into clinical efficacy. Newer experimental models of PD have attempted to reproduce the pathogenic process and to involve all areas of the brain pathologically affected in humans. In addition, models showing progressive neuronal death have been sought but so far unsuccessfully. Pathogenic modeling has been attempted using a range of toxins, as well as through the use of transgenic models of gene defects in familial PD and mutant rodent strains. However, there are still no accepted progressive models of PD that mimic the processes known to occur during cell death and that result in the motor deficits, pathology, biochemistry, and drug responsiveness as seen in humans. Nevertheless, functional models of PD have led to many advances in treating the motor symptoms of the disorder, and we have been fortunate to have them available. They are an important reason the treatment of PD is so much better compared with treatments for related illnesses. Ann Neurol 2008;64 (suppl):S16–S29
Url:
DOI: 10.1002/ana.21489
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Functional models of Parkinson's disease: A valuable tool in the development of novel therapies</title><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:74233C7E7AFF4A1534D71ADA7ABCBC866C2E92E9</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21489</idno><idno type="url">https://api.istex.fr/document/74233C7E7AFF4A1534D71ADA7ABCBC866C2E92E9/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000462</idno><idno type="wicri:Area/Main/Curation">000400</idno><idno type="wicri:Area/Main/Exploration">000D96</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Functional models of Parkinson's disease: A valuable tool in the development of novel therapies</title><author><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurodegenerative Disease Research Centre, School of Health and Biomedical Sciences, King's College, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="sub">Official Journal of the American Neurological Association and the Child Neurology Society</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-12">2008-12</date><biblScope unit="volume">64</biblScope><biblScope unit="issue">S2</biblScope><biblScope unit="supplement">2</biblScope><biblScope unit="page" from="S16">S16</biblScope><biblScope unit="page" to="S29">S29</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">74233C7E7AFF4A1534D71ADA7ABCBC866C2E92E9</idno><idno type="DOI">10.1002/ana.21489</idno><idno type="ArticleID">ANA21489</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Functional models of Parkinson's disease (PD) have led to effective treatment for the motor symptoms. Toxin‐based models, such as the 6‐hydroxydopamine–lesioned rat and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine–treated primate, have resulted in novel dopaminergic therapies and new therapeutic strategies. They have also been used to study processes underlying motor complications, particularly dyskinesia, and for developing pharmacological approaches to dyskinesia avoidance and suppression. Symptomatic models of PD based on nigrostriatal degeneration have a high degree of predictability of clinical effect of dopaminergic drugs on motor symptoms in humans. However, the effects of nondopaminergic drugs in these models do not translate effectively into clinical efficacy. Newer experimental models of PD have attempted to reproduce the pathogenic process and to involve all areas of the brain pathologically affected in humans. In addition, models showing progressive neuronal death have been sought but so far unsuccessfully. Pathogenic modeling has been attempted using a range of toxins, as well as through the use of transgenic models of gene defects in familial PD and mutant rodent strains. However, there are still no accepted progressive models of PD that mimic the processes known to occur during cell death and that result in the motor deficits, pathology, biochemistry, and drug responsiveness as seen in humans. Nevertheless, functional models of PD have led to many advances in treating the motor symptoms of the disorder, and we have been fortunate to have them available. They are an important reason the treatment of PD is so much better compared with treatments for related illnesses. Ann Neurol 2008;64 (suppl):S16–S29</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D96 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000D96 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:74233C7E7AFF4A1534D71ADA7ABCBC866C2E92E9
|texte= Functional models of Parkinson's disease: A valuable tool in the development of novel therapies
}}
| This area was generated with Dilib version V0.6.23. |  |